HALOZYME THERAPEUTICS, INC.

By person

25 insiders · 365 transactions

82.5×

Helen I. Torley holds 82.5 times base salary in stock. $82.57M of shares against $1.00M in salary for 2025.

Salary from the company's own proxy. The shares are what Helen I. Torley last reported holding, valued at $107.55, the price Common Stock was last bought or sold at on the open market here, on 11 Sep 2026.

Insider

Role

Bought

Sold

Net

Holding

Of company

Worth

Change

Torley Helen

PRESIDENT AND CEO

—

$96.56M (178) scheduled

−$96.56M

767,780

0.6765%

$82.57M

+568.1%

KIRK RANDAL J

10% owner

—

$61.57M (36)

−$61.57M

5,459,998

4.81%

$587.21M

−48.9%

LaBarre Michael J.

SVP, CHIEF TECHNICAL OFFICER

—

$25.02M (69) scheduled

−$25.02M

173,756

0.1531%

$18.69M

+10.5%

Posard Matthew L.

Director

—

$4.40M (8)

−$4.40M

77,835

0.0686%

$8.37M

−0.5%

LaBrosse Nicole

SVP, CHIEF FINANCIAL OFFICER

—

$3.91M (12) scheduled

−$3.91M

38,494

0.0339%

$4.14M

+664.8%

Kelley Kenneth J

Director

$748.70K (3)

$4.46M (11)

−$3.71M

179,833

0.1584%

$19.34M

−4.5%

Henderson Jeffrey William

Director

—

$3.32M (11)

−$3.32M

36,572

0.0322%

$3.93M

+37.5%

Daly James M

Director

—

$2.29M (4)

−$2.29M

20,503

0.0181%

$2.21M

+1.5%

Caudill Cortney

SVP, CHIEF OPERATING OFFICER

—

$2.23M (4) scheduled

−$2.23M

7,055

0.0062%

$758.75K

−8.1%

MATSUI CONNIE

Director

—

$2.16M (3)

−$2.16M

183,035

0.1613%

$19.69M

−18.0%

BIZZARI JEAN-PIERRE

Director

—

$1.44M (1)

−$1.44M

66,815

0.0589%

$7.19M

+81.5%

Connaughton Bernadette

Director

—

$1.28M (13) scheduled

−$1.28M

40,418

0.0356%

$4.35M

—

Krishnan Mahesh

Director

—

$547.80K (1) scheduled

−$547.80K

14,462

0.0127%

$1.56M

—

Chondros Dimitrios

SVP, Chief Medical Officer

—

$22.18K (1)

−$22.18K

38,584

0.0340%

$4.15M

+13.3%

Stelzer Laurie

SVP, Chief Financial Officer

—

116,167

0.1024%

$12.49M

+1,590%

LEONHARDT HARRY J

SVP, GC

—

66,373

0.0585%

$7.14M

+1,446%

Snyder Mark Howard

SVP, CHIEF LEGAL OFFICER

—

49,929

0.0440%

$5.37M

—

Countouriotis Athena

SVP and Chief Medical Officer

—

39,077

0.0344%

$4.20M

+95.6%

Miyashita Akiko Moni

Director

—

24,937

0.0220%

$2.68M

—

DUNCAN BARBARA GAYLE

Director

—

23,715

0.0209%

$2.55M

—

Matsuda Masaru

SVP, General Counsel

—

20,049

0.0177%

$2.16M

+346.6%

Sun Elaine D

SVP, Chief Financial Officer

—

14,018

0.0124%

$1.51M

—

Hickey Benjamin

SVP, Chief Commerical Officer

—

13,226

0.0117%

$1.42M

—

Lang James Paul

Director

—

4,685

0.0041%

$503.86K

—

RAMSAY DAVID A

EVP, PRESIDENT, DRUG DELIVERY

—

4,592

0.0040%

$493.86K

—

Individual transactions

Insider

Date

Role

Action

Price

Amount

Connaughton Bernadette

10 Aug 2026

Director

Sold on a plan

1,626

$102.80

$167.15K

Connaughton Bernadette

1 Jul 2026

Director

Sold on a plan

625

$77.21

$48.26K

Connaughton Bernadette

1 Jul 2026

Director

Sold on a plan

1,000

$76.40

$76.40K

Connaughton Bernadette

1 Jun 2026

Director

Sold on a plan

1,625

$66.21

$107.59K

Connaughton Bernadette

1 May 2026

Director

Sold on a plan

1,625

$63.48

$103.16K

Connaughton Bernadette

5 Jan 2026

Director

Sold on a plan

2,000

$70.25

$140.50K

Connaughton Bernadette

1 Dec 2025

Director

Sold on a plan

829

$71.60

$59.36K

Connaughton Bernadette

10 Nov 2025

Director

Sold on a plan

2,000

$68.48

$136.96K

Connaughton Bernadette

1 Oct 2025

Director

Sold on a plan

500

$75.70

$37.85K

Connaughton Bernadette

1 Oct 2025

Director

Sold on a plan

1,500

$75.09

$112.63K

LaBrosse Nicole

22 Sep 2025

SVP, CHIEF FINANCIAL OFFICER

Sold on a plan

314

$78.67

$24.70K

LaBrosse Nicole

22 Sep 2025

SVP, CHIEF FINANCIAL OFFICER

Sold on a plan

1,913

$77.83

$148.88K

Connaughton Bernadette

2 Sep 2025

Director

Sold on a plan

923

$74.11

$68.40K

Connaughton Bernadette

2 Sep 2025

Director

Sold on a plan

2,977

$73.62

$219.16K

Connaughton Bernadette

2 Sep 2025

Director

Sold on a plan

100

$71.71

$7.17K

Henderson Jeffrey William

28 Apr 2025

Director

Sold on a plan

200

$61.00

$12.20K

Henderson Jeffrey William

28 Apr 2025

Director

Sold on a plan

4,297

$60.34

$259.27K

Henderson Jeffrey William

1 Apr 2025

Director

Sold on a plan

503

$64.05

$32.22K

Henderson Jeffrey William

3 Mar 2025

Director

Sold on a plan

3,205

$59.12

$189.47K

Henderson Jeffrey William

3 Mar 2025

Director

Sold on a plan

1,795

$57.93

$103.99K

LaBarre Michael J.

27 Feb 2025

SVP, CHIEF TECHNICAL OFFICER

Sold on a plan

100

$58.74

$5.87K

LaBarre Michael J.

27 Feb 2025

SVP, CHIEF TECHNICAL OFFICER

Sold on a plan

1,597

$58.25

$93.03K

LaBarre Michael J.

26 Feb 2025

SVP, CHIEF TECHNICAL OFFICER

Sold on a plan

600

$58.65

$35.19K

LaBarre Michael J.

26 Feb 2025

SVP, CHIEF TECHNICAL OFFICER

Sold on a plan

9,400

$58.09

$546.06K

LaBarre Michael J.

25 Feb 2025

SVP, CHIEF TECHNICAL OFFICER

Sold on a plan

700

$58.67

$41.07K

LaBarre Michael J.

25 Feb 2025

SVP, CHIEF TECHNICAL OFFICER

Sold on a plan

9,300

$58.01

$539.47K

Henderson Jeffrey William

3 Feb 2025

Director

Sold on a plan

3,900

$56.41

$219.98K

Henderson Jeffrey William

3 Feb 2025

Director

Sold on a plan

1,100

$55.94

$61.54K

Henderson Jeffrey William

6 Jan 2025

Director

Sold on a plan

10,000

$50.01

$500.06K

LaBarre Michael J.

27 Feb 2024

SVP, CHIEF TECHNICAL OFFICER

Sold on a plan

10,000

$39.95

$399.46K

Showing 250 of 365 transactions. The figures above use every one of them.

HALOZYME THERAPEUTICS, INC.

By person

Individual transactions

What was left out